In this group, patients had founder mutations in DNA methylation genes, such as DNMT3A, TET2 and IDH1/2, and potentially epigenetic alterations drive progression to AML-MRC through blast growth [12]. The gene discussed is TET2; the disease is acute myeloid leukemia.